PWA
ADCT icon

Physician Wealth Advisors’s ADC Therapeutics ADCT Stock Holding History

Physician Wealth Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-228
Closed -$912 – 2030
2025
Q3 		$912 Buy
+228
New +$719 ﹤0.01% 1635

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Physician Wealth Advisors's ADCT Position: Q4 2025 in Review

Physician Wealth Advisors sold out of ADC Therapeutics (ADCT) in Q4 2025, closing a stake of 228 shares — an estimated $912 sold.

Physician Wealth Advisors first reported a position in ADCT in Q3 2025 and held it in 1 quarter. The position peaked at $912 in Q3 2025. 115 funds tracked by Wall St. Rank hold ADCT as of Q4 2025.

  • Physician Wealth Advisors reported no remaining ADC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Physician Wealth Advisors sold 228 ADC Therapeutics shares in Q4 2025, an estimated $912.
  • Physician Wealth Advisors first reported a position in ADC Therapeutics in Q3 2025 and held it in 1 quarter.
  • Physician Wealth Advisors's ADC Therapeutics position peaked at $912 in Q3 2025.
  • 115 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2025.

Based on Physician Wealth Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.